Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BTYNB (MDK6620) 是IMP1结合 c-Myc mRNA 的有效选择性抑制剂,IC50为 5 μM。它下调 β-TrCP1 mRNA 并减少NF-κB 的激活。它通过损害 IGF2 mRNA 结合蛋白 1 结合来破坏这种增强子功能,可用于癌症研究。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 265 | 现货 | ||
10 mg | ¥ 379 | 现货 | ||
25 mg | ¥ 659 | 现货 | ||
50 mg | ¥ 978 | 现货 | ||
100 mg | ¥ 1,470 | 现货 | ||
200 mg | ¥ 2,270 | 现货 | ||
500 mg | ¥ 3,890 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 323 | 现货 |
产品描述 | BTYNB (MDK6620) is an inhibitor of the oncofetal mRNA-binding protein IMP1 (IC50 = 5 μM for IMP1 binding to c-Myc mRNA). MDK6620 downregulates β-TrCP1 mRNA and reduces activation of nuclear transcriptional factors-kappa B (NF-κB). It disrupts this enhancer function by impairing IGF2 mRNA-binding protein 1 (IGF2BP1)-RNA association |
靶点活性 | IMP1 c-Myc mRNA internation:5 μM (IC50) |
体外活性 | In cells, BTYNB downregulates several mRNA transcripts regulated by IMP1.?BTYNB destabilizes c-Myc mRNA, resulting in downregulation of c-Myc mRNA and protein.?BTYNB downregulates β-TrCP1 mRNA and reduces activation of nuclear transcriptional factors-kappa B (NF-κB).?The oncogenic translation regulator, eEF2, emerged as a new IMP1 target mRNA, enabling BTYNB to inhibit tumor cell protein synthesis.?BTYNB potently inhibited proliferation of IMP1-containing ovarian cancer and melanoma cells with no effect in IMP1-negative cells.?Overexpression of IMP1 reversed BTYNB inhibition of cell proliferation.?BTYNB completely blocked anchorage-independent growth of melanoma and ovarian cancer cells in colony formation assays.?With its ability to target c-Myc and to inhibit proliferation of difficult-to-target melanomas and ovarian cancer cells, and with its unique mode of action, BTYNB is a promising small molecule for further therapeutic evaluation and mechanistic studies[1]. |
别名 | MDK6620, BTYNB IMP1 Inhibitor |
分子量 | 309.18 |
分子式 | C12H9BrN2OS |
CAS No. | 304456-62-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 62 mg/mL (200.53 mM)
Ethanol: 4 mg/mL (12.94 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 3.2344 mL | 16.1718 mL | 32.3436 mL | 80.859 mL |
5 mM | 0.6469 mL | 3.2344 mL | 6.4687 mL | 16.1718 mL | |
10 mM | 0.3234 mL | 1.6172 mL | 3.2344 mL | 8.0859 mL | |
DMSO | 20 mM | 0.1617 mL | 0.8086 mL | 1.6172 mL | 4.043 mL |
50 mM | 0.0647 mL | 0.3234 mL | 0.6469 mL | 1.6172 mL | |
100 mM | 0.0323 mL | 0.1617 mL | 0.3234 mL | 0.8086 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
BTYNB 304456-62-0 Cell Cycle/Checkpoint NF-Κb Others c-Myc NF-κB Inhibitor inhibit ES-2 IMP1 Myc MDK-6620 IGROV-1 MDK6620 MDK 6620 BTYNB IMP1 Inhibitor cancer cell SK-MEL2 inhibitor